News & Updates

Show Multimedia Only

Transcatheter ViV may be a safe short-term option to repeat MVR

18 Apr 2026 by

The transcatheter valve-in-valve (ViV) procedure appears to be a safe option for select patients requiring repeat surgery after failed mitral bioprostheses, according to findings from the randomized controlled SURViV trial presented at ACC.26. However, it is still early days for the ViV approach.

Transcatheter ViV may be a safe short-term option to repeat MVR

18 Apr 2026

Methotrexate may lower CV risk in psoriasis patients

17 Apr 2026 by

Patients with psoriasis who are treated with methotrexate (MTX) show a reduced incidence of metabolic syndrome and better cardiometabolic profiles, according to a study presented at AAD 2026.

Methotrexate may lower CV risk in psoriasis patients

17 Apr 2026

SURPASS-CVOT: Tirzepatide better than dulaglutide for cardiorenal outcomes

17 Apr 2026 by

Treatment with tirzepatide, a dual GLP-1* and GIP** agonist, significantly improves cardiovascular and renal outcomes in patients with diabetes and atherosclerotic cardiovascular disease (ASCVD) compared with dulaglutide, according to a post hoc analysis of the SURPASS-CVOT trial presented at ACC.26.

SURPASS-CVOT: Tirzepatide better than dulaglutide for cardiorenal outcomes

17 Apr 2026

SMART-DECISION: Stable post-MI patients can be safely taken off beta-blockers after 1 year

16 Apr 2026 by

Stopping beta-blockers after a year of regular use does not appear to increase the risk of adverse clinical outcomes in myocardial infarction (MI) survivors without evidence of left ventricular systolic dysfunction or heart failure (HF), as shown in the SMART-DECISION trial.

SMART-DECISION: Stable post-MI patients can be safely taken off beta-blockers after 1 year

16 Apr 2026

MetS risk higher in children with primary hypertension

16 Apr 2026

Children with hypertension, particularly those with primary hypertension, are vulnerable to developing metabolic syndrome (MetS), reveals a study.

MetS risk higher in children with primary hypertension

16 Apr 2026

ICLAD predicts poor vascular outcomes after ischaemic stroke

16 Apr 2026 by

The presence of intracranial large artery disease (ICLAD) is associated with poor composite vascular outcomes, myocardial infarction (MI), and vascular death, but not recurrence, in patients with acute ischaemic stroke, suggests a Singapore study.

ICLAD predicts poor vascular outcomes after ischaemic stroke

16 Apr 2026

Novel lithotripsy device fares well in PINNACLE-I trial

16 Apr 2026 by

The PINNACLE-I trial shows the feasibility, safety, and efficacy of LithiX, a novel Hertz contact intravascular lithotripsy (HC-IVL) device, for the treatment of calcified coronary artery lesions.

Novel lithotripsy device fares well in PINNACLE-I trial

16 Apr 2026

DASH diet, sodium reduction improve BP levels, but not BPV

15 Apr 2026

Both the Dietary Approaches to Stop Hypertension (DASH) diet and sodium intake reduction are effective in lowering absolute blood pressure (BP) levels, but these interventions do not yield significant benefits in BP variability (BPV), reports a study.

DASH diet, sodium reduction improve BP levels, but not BPV

15 Apr 2026

Mavacamten reduces blood flow obstruction in adolescents with HCM

14 Apr 2026 by

Treatment with mavacamten, compared with placebo, results in significantly greater reduction in left ventricular outflow tract (LVOT) obstruction over 28 weeks among adolescent patients with obstructive hypertrophic cardiomyopathy (HCM), as shown in the SCOUT-HCM trial.

Mavacamten reduces blood flow obstruction in adolescents with HCM

14 Apr 2026

ACS patients with SLE require greater healthcare use

13 Apr 2026

Systemic lupus erythematosus (SLE) patients with acute coronary syndrome (ACS) need a longer hospital stay and accrue higher charges, resulting in higher healthcare utilization, reports a study.

ACS patients with SLE require greater healthcare use

13 Apr 2026

News & Updates

Showing Cardiology articles

Showing

Specialty:

Transcatheter ViV may be a safe short-term option to repeat MVR

Transcatheter ViV may be a safe short-term option to repeat MVR

Methotrexate may lower CV risk in psoriasis patients

Methotrexate may lower CV risk in psoriasis patients

SURPASS-CVOT: Tirzepatide better than dulaglutide for cardiorenal outcomes

SURPASS-CVOT: Tirzepatide better than dulaglutide for cardiorenal outcomes

SMART-DECISION: Stable post-MI patients can be safely taken off beta-blockers after 1 year

SMART-DECISION: Stable post-MI patients can be safely taken off beta-blockers after 1 year

MetS risk higher in children with primary hypertension

MetS risk higher in children with primary hypertension

ICLAD predicts poor vascular outcomes after ischaemic stroke

ICLAD predicts poor vascular outcomes after ischaemic stroke

Novel lithotripsy device fares well in PINNACLE-I trial

Novel lithotripsy device fares well in PINNACLE-I trial

DASH diet, sodium reduction improve BP levels, but not BPV

DASH diet, sodium reduction improve BP levels, but not BPV

Mavacamten reduces blood flow obstruction in adolescents with HCM

Mavacamten reduces blood flow obstruction in adolescents with HCM

ACS patients with SLE require greater healthcare use

ACS patients with SLE require greater healthcare use